Amgen

Takeda, Amgen phase III motesanib trial fails

Friday, April 1, 2011 10:53 AM

Amgen, Takeda Pharmaceutical, and Millennium, a division of Takeda, announced unfavorable results from the MONET1 pivotal phase III trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer (NSCLC). The trial did not meet its primary objective of demonstrating an improvement in overall survival.

More... »

Amgen's Prolia shows positive results

Tuesday, March 29, 2011 12:58 PM

Amgen has presented new long-term data showing that women with osteoporosis who have been treated with Prolia for up to five years experienced statistically significant, year-to-year increases in lumbar spine and total hip bone mineral density.

More... »

Boehringer finalizes Amgen acquisition

Tuesday, March 29, 2011 10:25 AM

Boehringer has formally acquired Amgen's biopharmaceutical development and manufacturing facility in Fremont, Calif.

More... »

Cytel names Jim Baker VP

Tuesday, March 22, 2011 12:00 PM

Cambridge, Mass.-based Cytel, a provider of clinical trial design and implementation services and software, has named Jim Baker vice president of clinical research services.

More... »

Amgen to buy Pfizer plant, saving 280 jobs

Friday, March 11, 2011 01:53 PM

Amgen has agreed to buy a Pfizer manufacturing plant at Dun Laoghaire, County Dublin, securing 280 jobs in the process. The transaction is expected to close in the second quarter of the year, according to Fierce Pharma.

More... »

The CenterWatch Monthly, March 2011

Thursday, March 10, 2011 11:44 AM

CROs tackling investigative site success

More... »

Amgen announces phase III Xgeva results

Monday, March 7, 2011 07:40 AM

Amgen has announced results from a phase III study of 1,776 advanced cancer patients with different types of solid tumors (not including breast and prostate cancer) or multiple myeloma, which compared Xgeva (denosumab) to Zometa (zoledronic acid) in preventing skeletal-related events (SREs). The study found XGEVA was non-inferior to Zometa in delaying or preventing SREs.

More... »